SB5 vs Adalimumab Efficacy, Safety in Rheumatoid Arthritis

Share this content:
Patients with moderate to severe RA who were on methotrexate were randomly assigned to receive either SB5 or adalimumab 40 mg subcutaneously every other week.
Patients with moderate to severe RA who were on methotrexate were randomly assigned to receive either SB5 or adalimumab 40 mg subcutaneously every other week.

SB5, which has been approved by the European Commission as a biosimilar to adalimumab, demonstrated equivalent efficacy and similar safety compared with reference adalimumab in patients with rheumatoid arthritis (RA), according to a study published in Arthritis & Rheumatology.

In this phase 3, double-blind, parallel-group, 52-week study, researchers randomly assigned 544 patients with moderate to severe RA who were on methotrexate to receive either SB5 or adalimumab 40 mg subcutaneously every other week. Demographics and baseline characteristics were comparable between the SB5 and adalimumab groups, except for a statistically significant difference in mean age (49.8 vs 52.5 years, respectively, P =.010).

The primary efficacy end point — American College of Rheumatology 20% (ACR20) response rate at week 24 — was equivalent for patients receiving SB5 and adalimumab (72.4% and 72.2%, respectively; the adjusted difference of 0.1% [95%CI, -7.83% to 8.13%] was within the predefined equivalence margin). Similar responses between the groups were demonstrated for other efficacy end points, including ACR50 and ACR70 responses, time-response curves, and changes from baseline in disease activity. Patient age did not appear to affect the efficacy results.

The incidence of treatment-emergent adverse effects was similar between the groups (35.8% in the SB5 group and 40.7% in the adalimumab group up to week 24), as was the incidence of serious treatment-emergent adverse effects, serious infections, and injection site reactions. The groups also had comparable immunogenicity as demonstrated by the incidence of antidrug antibodies.

The authors found that SB5 appears to be equivalent to adalimumab in efficacy and safety in patients with RA. “SB5 was well tolerated and possessed comparable [pharmacodynamics], safety, and immunogenicity profiles to those of adalimumab,” the investigators concluded.

follow @RheumAdvisor

Reference

Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase 3 randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate to severe rheumatoid arthritis [published online September 26, 2017]. Arthritis Rheumatol.  doi:10.1002/art.40336

You must be a registered member of Rheumatology Advisor to post a comment.

Sign Up for Free e-newsletters